Showing results (41-50 of 1,545) with videos related to

Sort By:
Pageof 155
Medical Oncology (Northwood, London, England)|June 1, 1995
Successful matched unrelated transplantation from a donor with idiopathic thrombocytopenic purpura (ITP)M Delukina, Y Kapelushnik, R Or, et al.
Leukemia Research|November 26, 1999
The role of thiotepa in allogeneic stem cell transplantation in patients with leukemiaF Rosales, E Naparstek, G Varadi, et al.
Critical Reviews in Oncology/Hematology|June 22, 2001
Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseasesS Slavin, A Nagler, M Shapira, et al.
Transplantation|November 15, 1995
Elevated inflammatory cytokine levels in bone marrow graft rejectionA Nagler, R Or, B Nisman, et al.
Experimental Hematology|November 1, 1995
Ex vivo expansion of megakaryocyte precursors by preincubation of marrow allografts with interleukin-3 and granulocyte-macrophage colony-stimulating factor in vitroA Nagler, A Eldor, E Naparstek, et al.
Cancer|October 1, 1992
Low molecular weight heparin for Hickman catheter--induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantationP E Drakos, A Nagler, R Or, et al.
Gastroenterology|June 1, 1993
Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donorY Ilan, A Nagler, R Adler, et al.
Leukemia & Lymphoma|October 1, 1995
Recombinant human interleukin-6 accelerates in-vitro megakaryocytopoiesis and platelet recovery post autologous peripheral blood stem cell transplantationA Nagler, V R Deutsch, G Varadi, et al.
Reviews in Clinical and Experimental Hematology|August 7, 2001
Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disordersS Slavin, A Nagler, M Aker, et al.
The Journal of the Association of Physicians of India|April 1, 1993
Cutaneous hypersensitivity to co-trimoxazole after autologus bone marrow transplantation and immunotherapy with interferon alpha-2A and interleukin-2J Mehta, A Nagler, A Ackerstein, et al.
Pageof 155